Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Equillium Inc (EQ)
NASDAQ:EQ
Equillium (EQ) Stock Price & Analysis
645 Followers
EQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $3.25
Previous Close$0.68
Volume114.63K
Average Volume (3M)323.62K
Market Cap
$23.97M
Enterprise Value-$7.60M
Total Cash (Recent Filing)$32.28M
Total Debt (Recent Filing)$719.00K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 12, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding35,254,752
10 Day Avg. Volume251,678
30 Day Avg. Volume323,617
Standard Deviation0.44
R-Squared0.05
Alpha0.00510
Financial Highlights & Ratios
Price to Book (P/B)0.97
Price to Sales (P/S)2.19
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.20
Enterprise Value/Gross Profit-0.21
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$6.00Price Target Upside782.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Equillium News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEQ101 initial proof-of-concept data prove positive.
Financial ImpactIf Ono exercises its option, this would result in a payment of ¥5B—roughly $32.2M based on recent exchange rates—and significantly improve Equillium's balance sheet strength.
Safety ProfileEQ101 was well-tolerated with no serious adverse events and no notable changes in safety laboratory, electrocardiogram, vital signs, or physical exam findings were reported.
Bears Say
Comparative PerformanceSome of the weakness in EQ shares is likely due to investor views of modest efficacy relative to the JAK inhibitors and the higher-than-anticipated discontinuation rate.
EfficacyModest efficacy in more severe patients and an elevated discontinuation rate may underwhelm relative to investor expectations.
Market ReactionThe negative stock market reaction to the EQ101 data seems to have been driven mainly by concerns around the discontinuation rate seen in this trial.
---
Ownership Overview
31.38% Insiders
14.69% Mutual Funds
17.57% Other Institutional Investors
36.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.45 and its highest was $3.25 in the past 12 months.
What is Equillium Inc’s market cap?
Currently, no data Available
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Aug 12, 2024 which is in 36 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on May 09, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.068.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -$0.15.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 35,254,753 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went down -15%.
Which hedge fund is a major shareholder of Equillium Inc?
Among the largest hedge funds holding Equillium Inc’s share is Cota Capital Management, LLC. It holds Equillium Inc’s shares valued at 1M.
---
Equillium Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (782.48% Upside)
$6.00 (782.48% Upside)
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.65%
12-Months-Change
Fundamentals
Return on Equity
-48.17%
Trailing 12-Months
Asset Growth
-39.27%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
---
EQ Stock 12 Month Forecast
Average Price Target
$6.00
▲(782.48% Upside)
Technical Analysis
Best Analysts Covering EQ
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-23.14%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -23.14% per trade.
---